Abstract Number: 062 • 2023 Pediatric Rheumatology Symposium
Assessment of Barriers and Facilitators in Implementation of the Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans
Background/Purpose: Since 2010, the Childhood Arthritis and Rheumatology Research Alliance (CARRA) has developed 12 consensus treatment plans (CTP) with the aim of reducing treatment variability…Abstract Number: L17 • ACR Convergence 2022
Evaluating the Safety and Factors Associated with Treatment Cessation in Takayasu Arteritis
Background/Purpose: Immunosuppression in Takayasu Arteritis (TA) reduces the risk of arterial damage and disease progression. However, long-term use of glucocorticoids (GC) and other immunosuppressants carries…Abstract Number: 0121 • ACR Convergence 2022
Rheumatoid Arthritis Care Experiences of Black People Living in Canada: A Qualitative Study to Inform Treatment Guidelines
Background/Purpose: Guidelines may unintentionally introduce inequities in care through recommendations that do not reflect the realities of healthcare access and quality for persons who are…Abstract Number: 0357 • ACR Convergence 2022
Voclosporin Is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations
Background/Purpose: Pooled data from the Phase 2 AURA-LV and Phase 3 AURORA 1 studies demonstrated that adding voclosporin, a novel calcineurin inhibitor, to mycophenolate mofetil…Abstract Number: 1279 • ACR Convergence 2022
Development of ACR Longitudinal Digital Quality Measures for Systemic Lupus Erythematosus: A Literature Review and Modified Delphi Consensus Study
Background/Purpose: Significant morbidity and mortality urge efforts to improve quality of care for people with systemic lupus erythematosus (SLE). Yet, none of the 25 American…Abstract Number: 1284 • ACR Convergence 2022
Comparative Effectiveness Randomized Controlled Trials in Rheumatology Guidelines
Background/Purpose: Comparative effectiveness randomized controlled trials (RCTs) compare two active interventions in a head-to-head design. They are useful for informing clinical practice guidelines, but the…Abstract Number: 1671 • ACR Convergence 2022
Current Cervical Cancer Screening Guidelines Are Unsatisfactory for the Needs of Systemic Lupus Erythematosus Patients
Background/Purpose: HPV infection is a risk factor for cervical cancer. SLE patients have increased rates of HPV infection, cervical dysplasia and cancer. Present guidelines for…Abstract Number: 1765 • ACR Convergence 2022
Safety of the Recombinant Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis Treated with JAKi Drugs
Background/Purpose: Patients receiving treatment with JAK inhibitor drugs (JAKi) have an increased risk of developing herpes zoster (HZ). A new recombinant vaccine effective against HZ…Abstract Number: 1717 • ACR Convergence 2021
One Year After the Publication of the American College of Rheumatology (ACR) Guidelines for Management of Reproductive Health in Rheumatic Diseases, Has Anything Changed? An Analysis of Rheumatology Practice at a Tertiary Care Medical Center
Background/Purpose: Successful pregnancies in patients with rheumatic disease are possible when they are well-monitored, adequately treated, and planned during periods of disease quiescence. Previously, a…Abstract Number: 1810 • ACR Convergence 2021
Current Medication Practices and Preferences Among Patients with Psoriatic Arthritis (PsA)
Background/Purpose: The advent of targeted synthetics and biologics has greatly broadened the options for effective treatment in PsA. Guidelines published in 2018 by the American…Abstract Number: 0200 • ACR Convergence 2021
In Undifferentiated Arthritis, DMARD-treatment Intensified During the Last Decennia but Did Not Result in Improved Outcomes
Background/Purpose: International guidelines stress timely DMARD-initiation in early arthritis, also when classification-criteria are not yet fulfilled. Consequently, undifferentiated arthritis (UA)-patients are increasingly treated despite placebo-controlled…Abstract Number: 0517 • ACR Convergence 2021
TPMT and NUDT15 Genotype and Azathioprine Myelotoxicity in Patients with Inflammatory Conditions: Results from Real-World Clinical Practice
Background/Purpose: Azathioprine is frequently used for the treatment of several inflammatory conditions. However, treatment is often limited by adverse events, in particular myelotoxicity. Both thiopurine-S-methyltransferase…Abstract Number: 0606 • ACR Convergence 2021
How Might We Care for Rheumatoid Arthritis (RA) Patients Unable to See a Rheumatologist And/or Use Certain of Our Medications? Proposed Preliminary Recommendations for RA Patients Who Don’t Meet Our Established Guidelines
Background/Purpose: Physicians share responsibilities to promote social justice and assure equitable healthcare for all. Street medicine (SM) is a field dedicated to address the need…Abstract Number: 0648 • ACR Convergence 2021
Improving Post-Rituximab Hypogammaglobulinemia Risk Assessments: A Fellows’ Quality Improvement Initiative
Background/Purpose: Hypogammaglobulinemia following rituximab therapy is a potentially severe complication that can lead to infection-related morbidity and mortality. If recognized, clinicians may prevent infections by…Abstract Number: 0653 • ACR Convergence 2021
Adherence to the 2015 ACR Guidelines for the Management of Polymyalgia Rheumatica and Screening for Osteoporosis at a Tertiary Care Medical Center
Background/Purpose: Since the first description of polymyalgia rheumatica (PMR) in the early 1950s, the ideal dose and duration of glucocorticoid therapy has varied. In 2015,…
ACR Meeting Abstracts